Want to see SE:BONEX full AI Analyst Report?
BONEX Stock Chart & Stats
kr184.80
-kr10.40(-2.96%)
At close: 4:00 PM EST
kr184.80
-kr10.40(-2.96%)
Day’s Range― - ―
52-Week Rangekr165.00 - kr346.40
Previous CloseN/A
Volume90.84K
Average Volume (3M)318.62K
Market Cap
kr14.75B
Enterprise Valuekr13.27B
Total Cash (Recent Filing)kr455.26M
Total Debt (Recent Filing)kr14.10M
Price to Earnings (P/E)85.4
Beta0.69
Next Earnings
Jul 16, 2026EPS Estimate
1.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.81
Shares Outstanding65,859,190
10 Day Avg. Volume295,837
30 Day Avg. Volume318,624
Financial Highlights & Ratios
PEG Ratio14.80
Price to Book (P/B)14.28
Price to Sales (P/S)10.54
P/FCF Ratio56.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.81
Revenue Forecast (FY)kr1.50B
Bulls Say, Bears Say
Bulls Say
Very High Gross Margins And Strong Operating ProfitabilitySustained gross margins near 95% reflect a differentiated bioceramic platform and pricing power in hospital procedures. High margins provide structural operating leverage as volume scales, enabling reinvestment in commercial expansion and R&D while supporting durable operating profitability over the next 2–6 months.
Strong Cash Generation And Conservative Balance SheetOperating cash flow now exceeds net income and cash reserves are sizeable with minimal leverage, giving the company flexibility to fund sales hires and EUROW investment without near-term financing risk. This cash strength supports durable execution of growth plans and cushions against cyclical stress.
Robust U.S. Product MomentumAccelerating U.S. sales for CERAMENT G indicate growing surgeon adoption and market penetration in the largest market. Durable U.S. volume growth underpins scalable revenue expansion, improves mix toward higher‑value antibiotic‑eluting products, and strengthens future reimbursement and commercial leverage.
Bears Say
Regulatory Timing Uncertainty For CERAMENT VDelays in the De Novo approval process create structural timing risk for U.S. market access and the associated NTAP reimbursement. A slip beyond 2026 would postpone material incremental revenue and any reimbursement benefit, extending the payback horizon for recent commercial investments.
New U.S. Tariff Introduces A Durable Margin HeadwindA permanent tariff raising cost of goods sold reduces per‑unit margins in the strategically important U.S. market. That structural cost pressure weakens unit economics, limits funding for sales expansion unless offset by pricing or efficiency, and reduces incremental margin on future U.S. growth.
Historical Volatility In Cash Flow And ReturnsAlthough cash conversion has improved recently, prior multi‑year negative cash flow and volatile ROE indicate earnings power has been uneven. This history suggests the current positive cash profile may be vulnerable to slower adoption or reimbursement setbacks, making durability of recent gains an open question.
BONESUPPORT HOLDING AB News
BONEX FAQ
What was BONESUPPORT HOLDING AB’s price range in the past 12 months?
BONESUPPORT HOLDING AB lowest stock price was kr165.00 and its highest was kr346.40 in the past 12 months.
What is BONESUPPORT HOLDING AB’s market cap?
BONESUPPORT HOLDING AB’s market cap is kr14.75B.
When is BONESUPPORT HOLDING AB’s upcoming earnings report date?
BONESUPPORT HOLDING AB’s upcoming earnings report date is Jul 16, 2026 which is in 5 days.
How were BONESUPPORT HOLDING AB’s earnings last quarter?
BONESUPPORT HOLDING AB released its earnings results on Apr 22, 2026. The company reported kr0.805 earnings per share for the quarter, missing the consensus estimate of kr0.965 by -kr0.16.
Is BONESUPPORT HOLDING AB overvalued?
According to Wall Street analysts BONESUPPORT HOLDING AB’s price is currently Overvalued.
Does BONESUPPORT HOLDING AB pay dividends?
BONESUPPORT HOLDING AB does not currently pay dividends.
What is BONESUPPORT HOLDING AB’s EPS estimate?
BONESUPPORT HOLDING AB’s EPS estimate is 1.13.
How many shares outstanding does BONESUPPORT HOLDING AB have?
BONESUPPORT HOLDING AB has 65,859,190 shares outstanding.
What happened to BONESUPPORT HOLDING AB’s price movement after its last earnings report?
BONESUPPORT HOLDING AB reported an EPS of kr0.805 in its last earnings report, missing expectations of kr0.965. Following the earnings report the stock price went down -1.167%.
Which hedge fund is a major shareholder of BONESUPPORT HOLDING AB?
Currently, no hedge funds are holding shares in SE:BONEX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BONESUPPORT HOLDING AB
Bonesupport Holding AB (publ) is an orthobiologics company that specializes in the development and commercialization of injectable bioceramic bone graft substitutes. These products are utilized for treating bone voids and are available internationally, including in Europe and North America. Among its key offerings are CERAMENT Bone Void Filler, a synthetic, injectable, moldable, and drillable solution comprising hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol. Additionally, the company provides CERAMENT G, an injectable ceramic bone graft substitute infused with gentamicin, and CERAMENT V, a synthetic bone void filler containing vancomycin. Bonesupport is also advancing preclinical product candidates focused on promoting bone regrowth. These future solutions are being developed for applications such as trauma, revision arthroplasty, chronic osteomyelitis, oncology, and bone and foot infections related to diabetes. Founded in 1999, the company maintains its headquarters in Lund, Sweden.
BONEX Company Deck
BONEX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational picture: strong underlying demand and significant constant-currency revenue growth (notably in the U.S. for CERAMENT G), high gross margins, solid adjusted profitability and robust cash generation. Strategic progress was highlighted by clinical publications, first sales in India, early spine activity, and a favorable CMS proposed ruling that could materially improve reimbursement. Offsetting risks include material currency translation headwinds that reduced reported growth, a tariff-driven margin headwind in the U.S., higher short‑term commercial and incentive costs that will press margins while investments ramp, early-stage/soft BVF spine revenues and timing uncertainty around the CERAMENT V De Novo approval. On balance, the positives (strong growth momentum, cash generation, margin levels, reimbursement progress) materially outweigh the challenges.View all SE:BONEX earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---